Searchable abstracts of presentations at key conferences in endocrinology

ea0063p986 | Diabetes, Obesity and Metabolism 3 | ECE2019

Weight loss in PCOS - benefits of Metformin and Liraglutide - a single institution experience

Griffin Ciara , McGowan Elaine , Griffin Margaret

Obesity commonly occurs in PCOS and contributes to increased metabolic risk and low self esteem. Advice on weight loss underpins all management strategies in the obese lady with PCOS but weight loss can remain elusive despite best efforts. We wished to determine how diet advice alone compared to metformin and/or liraglutide in our patients.Methods: We conducted an observational retrospective anonymized review of patients attending an endocrinology clinic...

ea0077lb18 | Late Breaking | SFEBES2021

Prevalence rate of undiagnosed diabetes in an asymptomatic population

Hughes Harry , McKenna Susan , O'Kelly Sara , Moran Carla , Griffin Margaret

Background and Aim: Approximately 1500 people attend the Beacon Health Check Department annually involving a panel of blood tests being screened. Our aim was to compare what percentage of this asymptomatic population have diabetes or were pre-diabetic and what percentage of these were undiagnosed and therefore untreated conditions.Methodology: This audit was a retrospective review of data collected from patients attending the Beacon Hospital Health Check...

ea0056p724 | Clinical case reports - Pituitary/Adrenal | ECE2018

Two year old follow up of Hypophysitis secondary to the checkpoint inhibitor Pembrolizumab - a case report

Anderson Cian , Griffin James , McKenna Susan , Santos Ana , Westrup Jenny , Kelleher Fergal , Griffin Margaret

Ipilimumab (an anti-CTLA-4 antibody) treatment has been associated with Immune Related Adverse Events (iRAEs) of the endocrine system. However the frequency of iRAEs in programmed cell death (PD-1) receptor agent use is incompletely characterised, though initial studies report an incidence of 0.5%. We present a case of Pembrolizumab-induced hypophysitis in a 47 yo. male with melanoma. Presenting in 2007 with an initial diagnosis of melanoma, with lymph node recurrence in 2013....

ea0063p1045 | Interdisciplinary Endocrinology 2 | ECE2019

Clinical audit of immune related adverse events of the endocrine system with checkpoint inhibitor therapies – adopting a new algorithm for routine endocrine monitoring

Anderson Cian , Sheehan David , Ronan Karine , Othman Elly Hanis Che , McKenna Susan , McDermott Ray , Westrup Jennifer , Griffin Margaret

Background: Immune related adverse events (iRAEs) of the endocrine system are commonly recognised in Checkpoint Inhibitor Therapy treatment with current research suggesting clinically significant endocrinopathies occur in 10%. As the use of these drugs continues to rise, so too does the importance of routine endocrine monitoring in order to avoid potentially life-threatening adverse-events.Aims: To establish the frequency, severity, management and outcom...